Norepinephrine dysfunction in depression.

A Anand; D S Charney

Home/Archive/PubMed

PubMed · 10910013

Norepinephrine dysfunction in depression.

A Anand·D S Charney

View original source ↗Export metadata ↓

Abstract

The study of the noradrenergic neurotransmitter system remains one of the cornerstones of depression research. Better understanding of the action of norepinephrine and other catecholamines at the synaptic and intracellular level holds the potential for providing clues to the etiology of depression and introduces exciting possibilities for the development of novel medications for the treatment of depression. The following review of norepinephrine as it relates to depression will shed light on the current understanding of the noradrenergic system and the role for selective norepinephrine reuptake inhibitors (selective NRIs) in the treatment of depression.

Explore related subjects

Adrenergic Uptake Inhibitors Antidepressive Agents Depressive Disorder Down-Regulation Drug Design Humans Locus Coeruleus Models, Biological Norepinephrine Receptors, Adrenergic Receptors, Adrenergic, alpha Receptors, Adrenergic, beta Signal Transduction Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

A Anand, D S Charney. 2000. Norepinephrine dysfunction in depression.. https://pubmed.ncbi.nlm.nih.gov/10910013/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

6-Hydroxydopamine-lesioning of the nigrostriatal pathway in rats alters basal ganglia mRNA for copper, zinc- and manganese-superoxide dismutase, but not glutathione peroxidase.

The effects of nigrostriatal pathway destruction on the mRNA levels of copper, zinc-dependent superoxide dismutase (Cu,Zn-SOD), manganese-dependent superoxide dismutase (Mn-SOD), and glutathione peroxidase in basal ganglia of adult rat were investigated using in situ hybridization histochemistry and oligodeoxynucleotide (single-stranded complementary DNA) probes. The 6-hydroxydopamine (6-OHDA)-induced destruction of the nigrostriatal pathway resulted in contralateral rotation to apomorphine and a marked loss of specific [(3)H]mazindol binding in the striatum (93%; P<0.05) and of tyrosine hydroxylase mRNA in substantia nigra pars compacta (SC) (93%; P<0.05) compared with control rats. Levels of Cu,Zn-SOD mRNA were decreased in the striatum, globus pallidus, and SC on the lesioned side of 6-OHDA-lesioned rats compared with sham-lesioned rats (P<0.05). Levels of Mn-SOD mRNA were increased in the nucleus accumbens (P<0.05), but decreased in the SC (P<0.05) on the lesioned side of 6-OHDA-treated rats compared with sham-lesioned rats. Lesioning with 6-OHDA had no effect on glutathione peroxidase mRNA levels in any region of basal ganglia examined. The significant changes in Cu,Zn-SOD and Mn-SOD mRNA indicate that SOD is primarily expressed by dopaminergic neurons of the nigrostriatal pathway, and that the Mn-SOD gene appears to be inducible in rat basal ganglia in response to both physical and chemical damage 5 weeks after 6-OHDA-lesioning. These findings may clarify the status of antioxidant enzymes, particularly Mn-SOD, in patients with Parkinson's disease and their relevance to disease pathogenesis.

Adrenergic Uptake Inhibitors↗

PubMed2001

Functional characterization of the splicing variants of human norepinephrine transporter.

Human norepinephrine transporter (NET) displays three splicing variants having different carboxy terminals, hNET, hNET C-t var1 and hNET C-t var2. Functional characterization of these isoforms was performed with transient expression system in COS-7 cells. Cells transfected with hNET C-t var2, but not hNET C-t var1, revealed a significant increase in [(3)H]norepinephrine (NE) uptake and [(3)H]nisoxetine binding as well as hNET, in association with their different cellular localization indicated by immunostaining using NET-specific antisera. Kinetic and pharmacological analyses of [(3)H]NE uptake revealed different characteristics between hNET and hNET C-t var2. These results suggest that hNET C-t var2 may participate in NE transport in a manner different from hNET at noradrenergic synapses or in other tissues including placenta where NET variants were found to exist.

Adrenergic Uptake Inhibitors↗

PubMed2001

Differential time-course profiles of dopamine release and uptake changes induced by three dopamine uptake inhibitors.

Using real-time voltammetry, we compared the effects of cocaine (1.0, 3.0, or 10 microM), WIN 35428 (0.1, 0.5, or 2.0 microM), and nomifensine (0.2, 1.0, or 5.0 microM) on electrically evoked dopamine release and uptake in the rat accumbens slice. The time course for onset and offset of the drug effects were determined by perfusing single drug concentration for 30 min, followed by a 60-min washout. Cocaine elicited a rapid, concentration-independent increase in dopamine release and a more gradual, concentration-dependent inhibition of uptake. During washout, uptake inhibition rapidly abated to near baseline values. During the same period, the potentiation of dopamine release exhibited a slower offset for all concentrations and, for 10 microM cocaine, was even greater than that observed during drug perfusion ("rebound" increase). The release rebound was not observed during continuous 90-min perfusion, verifying that cocaine washout per se was a sufficient condition. Selective D1 or D2 antagonists (0.5 microM SCH 39166 or 2 microM sulpiride, respectively) were without effect on cocaine-induced release alterations. WIN 35428 and nomifensine induced similar changes in dopamine kinetics during perfusion. However, in contrast to cocaine, no consistent release rebound was observed during their washout. For 2 microM WIN 38425, washout and continuous perfusion groups exhibited similar changes in dopamine release and uptake. The time-course mismatch between uptake inhibition and DA release potentiation as well as release rebound during washout suggests that altered dopamine release might play a role in behavioral effects of cocaine.

Adrenergic Uptake Inhibitors↗